论文部分内容阅读
法国研究者de Gramont等的研究结果显示,Ⅲ期结肠癌患者辅助化疗加入贝伐珠单抗未带来显著无病生存获益,总生存亦无明显获益,因此不宜推荐贝伐珠单抗用于Ⅲ期结肠癌患者根治性切除术后辅助治疗。
French researchers de Gramont et al. The results showed that adjuvant chemotherapy with adjuvant chemotherapy in patients with stage III did not bring significant disease-free survival benefit, and no significant benefit in overall survival. Therefore, bevacizumab Used for postoperative adjuvant chemotherapy in patients with stage Ⅲ colon cancer.